** Shares of drug developer Cargo Therapeutics CRGX.O fall 77.4% to record low of $2.99
** On Wednesday, CRGX said it is stopping a mid-stage trial for cancer treatment
** Trial was stopped due to serious side effects in some patients, including a severe inflammatory condition - CRGX
** CRGX has $368.1 million in cash and expects it to last until mid-2028
** CRGX also said it is reducing its workforce by about 50%
** As of Sept. 30, 2024, co had 170 full-time employees - SEC filing
** CRGX fell 36.5% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。